Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

abstract：:By merging computational systems modeling and experimental approaches, we have uncovered treatments reprogramming pro-angiogenic monocytes present in breast tumor into immunologically potent cells capable of mediating an anti-tumor immune response. The unraveled pathways and ligands which underlie monocyte pro-angioge...

journal_title：Oncoimmunology

authors： Doucey MA,Xenarios I

更新日期：2015-07-07 00:00:00

abstract：:Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

journal_title：Oncoimmunology

authors： Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

更新日期：2018-01-29 00:00:00

abstract：:Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMX...

journal_title：Oncoimmunology

authors： Weiss JM,Guérin MV,Regnier F,Renault G,Galy-Fauroux I,Vimeux L,Feuillet V,Peranzoni E,Thoreau M,Trautmann A,Bercovici N

更新日期：2017-07-07 00:00:00

abstract：:Breast cancer spread to distant sites is often incurable. Our recent findings demonstrate that Type I interferons secreted by tumor cells induce anti-metastatic immune responses that prevent breast cancer metastasis to the bone. This provides novel insights into the importance of the crosstalk between neoplastic and i...

journal_title：Oncoimmunology

authors： Slaney CY,Möller A,Hertzog PJ,Parker BS

更新日期：2013-01-01 00:00:00

abstract：:The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...

journal_title：Oncoimmunology

authors： Kuhn S,Ronchese F

更新日期：2013-11-01 00:00:00

abstract：:CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

journal_title：Oncoimmunology

authors： Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

更新日期：2018-02-01 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

journal_title：Oncoimmunology

authors： Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

更新日期：2018-10-31 00:00:00

abstract：:Triple-negative breast cancer (TNBC) is characterized by broad genomic and transcriptional heterogeneity and results in a worse prognosis than other breast cancer types. Here, we integrated genomic and transcriptomic data combined with clinicopathologic information from 538 patients with TNBC and identified four novel...

journal_title：Oncoimmunology

authors： Chen H,Chong W,Yang X,Zhang Y,Sang S,Li X,Lu M

更新日期：2020-06-30 00:00:00

abstract：:The immune microenvironment in follicular lymphoma (FL) plays an important role in controlling disease characteristics. To characterize the T-cell receptor (TCR) repertoire in follicular lymphoma (FL) tissues, we applied a next-generation sequencing platform and deeply sequenced TCR cDNAs of T-cell subset populations ...

journal_title：Oncoimmunology

authors： Liu X,Venkataraman G,Lin J,Kiyotani K,Smith S,Montoya M,Nakamura Y,Kline J

更新日期：2015-02-03 00:00:00

abstract：:A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid ...

journal_title：Oncoimmunology

authors： Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

更新日期：2013-11-01 00:00:00

abstract：:T lymphocytes, which recognize antigen peptides through specific T cell receptors (TCRs), play an important role in the human adaptive immune response. TCR diversity is closely associated with host immune response and cancer prognosis. Although tumor-infiltrating T lymphocytes have implications for tumor prognosis, fe...

journal_title：Oncoimmunology

authors： Chen Y,Xu Y,Zhao M,Liu Y,Gong M,Xie C,Wu H,Wang Z

更新日期：2016-08-05 00:00:00

abstract：:Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human in vitro expanded and flow-sorted ...

journal_title：Oncoimmunology

authors： Coman T,Rossignol J,D'Aveni M,Fabiani B,Dussiot M,Rignault R,Babdor J,Bouillé M,Herbelin A,Coté F,Moura IC,Hermine O,Rubio MT

更新日期：2018-08-23 00:00:00

abstract：:In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

journal_title：Oncoimmunology

authors： Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

更新日期：2014-12-21 00:00:00

abstract：:The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. Here, ...

journal_title：Oncoimmunology

authors： Harwood SL,Alvarez-Cienfuegos A,Nuñez-Prado N,Compte M,Hernández-Pérez S,Merino N,Bonet J,Navarro R,Van Bergen En Henegouwen PMP,Lykkemark S,Mikkelsen K,Mølgaard K,Jabs F,Sanz L,Blanco FJ,Roda-Navarro P,Alvarez-Vallina L

更新日期：2017-09-27 00:00:00

abstract：:The instauration of an immunosuppressive microenvironment is a key event in cancer development and progression. Here, we discuss increasing evidences of the crosstalk between myeloid-derived suppressor cells (MDSCs) and mast cells (MCs) as a new fuel for the cancer immunosuppressive machinery. ...

journal_title：Oncoimmunology

authors： Danelli L,Frossi B,Pucillo CE

更新日期：2015-03-24 00:00:00

abstract：:Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the conte...

journal_title：Oncoimmunology

authors： Koido S,Homma S,Okamoto M,Namiki Y,Takakura K,Uchiyama K,Kajihara M,Arihiro S,Imazu H,Arakawa H,Kan S,Komita H,Ito M,Ohkusa T,Gong J,Tajiri H

更新日期：2013-05-01 00:00:00

abstract：:B cells are generally believed to operate as producers of high affinity antibodies to defend the body against microorganisms, whereas cellular cytotoxicity is considered as an exclusive prerogative of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In conflict with this dogma, recent studies have demonst...

journal_title：Oncoimmunology

authors： Hagn M,Jahrsdörfer B

更新日期：2012-11-01 00:00:00

abstract：:Anticancer immunotherapies are highly desired. Conversely, unwanted inflammatory or immune responses contribute to oncogenesis, tumor progression, and cancer-related death. For non-immunogenic therapies to inhibit tumor growth, they must promote, not prevent, the activation of anticancer immune responses. Here, the ce...

journal_title：Oncoimmunology

authors： Issazadeh-Navikas S

更新日期：2013-12-01 00:00:00

abstract：:TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

journal_title：Oncoimmunology

authors： Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

更新日期：2017-09-21 00:00:00

abstract：:Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based ther...

journal_title：Oncoimmunology

authors： Dhodapkar KM,Gettinger SN,Das R,Zebroski H,Dhodapkar MV

更新日期：2013-07-01 00:00:00

abstract：:The presence of tumor-infiltrating lymphocytes (TILs) is a strong prognostic parameter for local dissemination and overall survival in melanoma. Lymphocyte migration from blood into peripheral tissues is mainly regulated by vascular endothelium. However, the blood vessels and mechanisms governing the recruitment of TI...

journal_title：Oncoimmunology

authors： Martinet L,Le Guellec S,Filleron T,Lamant L,Meyer N,Rochaix P,Garrido I,Girard JP

更新日期：2012-09-01 00:00:00

abstract：:Inflammatory chemokines are critical contributors in attracting relevant immune cells to the tumor microenvironment and driving cellular interactions and molecular signaling cascades that dictate the ultimate outcome of host anti-tumor immune response. Therefore, rational application of chemokines in a spatial-tempora...

journal_title：Oncoimmunology

authors： Allen F,Bobanga ID,Rauhe P,Barkauskas D,Teich N,Tong C,Myers J,Huang AY

更新日期：2017-11-20 00:00:00

abstract：:Donor lymphocyte infusion (DLI) is an established and potentially curative immune therapy for relapsed leukemia after hematopoietic stem cell transplant (HSCT). Herein, we describe the utility of DLI as a tractable model system to glean fresh insights into understanding and predicting effective anti-leukemia immunity....

journal_title：Oncoimmunology

authors： Bachireddy P,Wu CJ

更新日期：2014-03-17 00:00:00

abstract：:Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broa...

journal_title：Oncoimmunology

authors： Somaiah N,Chawla SP,Block MS,Morris JC,Do K,Kim JW,Druta M,Sankhala KK,Hwu P,Jones RL,Gnjatic S,Kim-Schulze S,Tuballes K,Yishak M,Lu H,Yakovich A,Ter Meulen J,Chen M,Kenney RT,Bohac C,Pollack SM

更新日期：2020-11-19 00:00:00

abstract：:Recent studies on the processes that lead to the development of pancreatic cancer indicate that inflammatory macrophages have key functions in the initiation of pre-neoplastic lesions. Specifically, acquisition of an activating Kras mutation in pancreatic acinar cells leads to upregulation of intercellular adhesion mo...

journal_title：Oncoimmunology

authors： Storz P

更新日期：2015-03-19 00:00:00

abstract：:Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microenvironment. In this...

journal_title：Oncoimmunology

authors： Hagihara K,Chan S,Zhang L,Oh DY,Wei XX,Simko J,Fong L

更新日期：2018-10-01 00:00:00

abstract：:We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

journal_title：Oncoimmunology

authors： McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

更新日期：2012-07-01 00:00:00

abstract：:Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

journal_title：Oncoimmunology

authors： Houot R,Kohrt H,Levy R

更新日期：2012-09-01 00:00:00

abstract：:Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies....

journal_title：Oncoimmunology

authors： Somerville RP,Dudley ME

更新日期：2012-11-01 00:00:00